Jayakumar Mani

机构：Regeneron (United States) · ORCID：0000-0003-3147-0753

发表论文 38 篇 · 总被引 366 次 · h-index 6

代表论文

• Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: a single-arm, open-label, phase 2 trial (2022 · ˜The œLancet. Gastroenterology & hepatology · 被引 234)
• Phase I Study of Fianlimab, a Human Lymphocyte Activation Gene-3 (LAG-3) Monoclonal Antibody, in Combination With Cemiplimab in Advanced Melanoma (2024 · Journal of Clinical Oncology · 被引 41)
• Clinical activity of fianlimab (REGN3767), a human anti-LAG-3 monoclonal antibody, combined with cemiplimab (anti-PD-1) in patients (pts) with advanced melanoma. (2021 · Journal of Clinical Oncology · 被引 30)
• Significant durable response with fianlimab (anti-LAG-3) and cemiplimab (anti-PD-1) in advanced melanoma: Post adjuvant PD-1 analysis. (2023 · Journal of Clinical Oncology · 被引 15)
• A phase 1 study of fianlimab (anti–LAG-3) in combination with cemiplimab (anti–PD-1) in patients with advanced HNSCC. (2024 · Journal of Clinical Oncology · 被引 8)
• A phase 1 study of fianlimab (anti-LAG-3) in combination with cemiplimab (anti-PD-1) in patients with advanced ccRCC. (2024 · Journal of Clinical Oncology · 被引 7)